Home Casteddu.com	FAQ My Amedeo About	Flying Publisher
	The Medical Article of the Year 2008: Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-78. Free full-text

Lung Cancer

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 45 articles: HTML format

Single Articles

May 2008
1. LEGGAS M , Kuo KL, Robert F, Cloud G, et al
   Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy.
   Cancer Chemother Pharmacol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   April 2008
2. FELIU J , Firvida JL, Castro J, Madronal C, et al
   Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study.
   Cancer Chemother Pharmacol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   March 2008
3. JACKSON T , Chougule MB, Ichite N, Patlolla RR, et al
   Antitumor activity of noscapine in human non-small cell lung cancer xenograft model.
   Cancer Chemother Pharmacol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
4. YAMAMOTO N , Horiike A, Fujisaka Y, Murakami H, et al
   Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
   Cancer Chemother Pharmacol. 2008;61:489-96.
   PubMed     Related articles    Abstract available
   
   
   February 2008
5. CHOI B , Robins HI, Schiller J, Mehta M, et al
   A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer.
   Cancer Chemother Pharmacol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
6. HACKER A , Marton LJ, Sobolewski M, Casero RA Jr, et al
   In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells.
   Cancer Chemother Pharmacol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
7. PARK SH , Cho EK, Kim Y, Kyung SY, et al
   Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
   Cancer Chemother Pharmacol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   January 2008
8. HORTI J , Juhasz E, Monostori Z, Maeda K, et al
   Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer.
   Cancer Chemother Pharmacol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
9. HSU TS , Chen C, Lee PT, Chiu SJ, et al
   7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway.
   Cancer Chemother Pharmacol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
10. FINE RL , Fogelman DR, Schreibman SM, Desai M, et al
    The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
    Cancer Chemother Pharmacol. 2008;61:167-75.
    PubMed     Related articles    Abstract available
    
    
    December 2007
11. LEE I , Shogen K
    Mechanisms of enhanced tumoricidal efficacy of multiple small dosages of ranpirnase, the novel cytotoxic ribonuclease, on lung cancer.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    November 2007
12. SAIF MW , Sellers S, Li M, Wang W, et al
    A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
    Cancer Chemother Pharmacol. 2007;60:871-82.
    PubMed     Related articles    Abstract available
    
    
    
13. OKU H , Wongtangtintharn S, Iwasaki H, Inafuku M, et al
    Tumor specific cytotoxicity of glucosylceramide.
    Cancer Chemother Pharmacol. 2007;60:767-75.
    PubMed     Related articles    Abstract available
    
    
    October 2007
14. OSHITA F , Yamada K, Saito H, Noda K, et al
    Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
15. STINCHCOMBE TE , Socinski MA, Walko CM, O'Neil BH, et al
    Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
    Cancer Chemother Pharmacol. 2007;60:759-66.
    PubMed     Related articles    Abstract available
    
    
    
16. SHIBATA MA , Akao Y, Shibata E, Nozawa Y, et al
    Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation.
    Cancer Chemother Pharmacol. 2007;60:681-91.
    PubMed     Related articles    Abstract available
    
    
    August 2007
17. TOMONAGA N , Nakamura Y, Soda H, Nagashima S, et al
    Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
18. SATO H , Fukumoto K, Hada S, Hagiwara H, et al
    Enhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cells.
    Cancer Chemother Pharmacol. 2007;60:449-57.
    PubMed     Related articles    Abstract available
    
    
    
19. IZZEDINE H , Buhaescu I, Rixe O, Deray G, et al
    Sunitinib malate.
    Cancer Chemother Pharmacol. 2007;60:357-64.
    PubMed     Related articles    Abstract available
    
    
    July 2007
20. PIANTEDOSI FV , Caputo F, Mazzarella G, Gilli M, et al
    Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
21. MU D , Zhang W, Chu D, Liu T, et al
    The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    June 2007
22. OKUDA K , Hirose T, Ishida H, Kusumoto S, et al
    Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
23. CHOI HJ , Cho BC, Shin SJ, Cheon SH, et al
    Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
24. TAS F , Duranyildiz D, Soydinc HO, Cicin I, et al
    Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
25. WANG LR , Huang MZ, Zhang GB, Xu N, et al
    Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
26. ZASTRE J , Anantha M, Ramsay E, Bally M, et al
    Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line.
    Cancer Chemother Pharmacol. 2007;60:91-102.
    PubMed     Related articles    Abstract available
    
    
    May 2007
27. LI J , Viallet J, Haura EB
    A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
28. OHYANAGI F , Horiike A, Okano Y, Satoh Y, et al
    Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
29. JORGENSEN TJ , Tian H, Joseph IB, Menon K, et al
    Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Cancer Chemother Pharmacol. 2007;59:725-32.
    PubMed     Related articles    Abstract available
    
    
    March 2007
30. TABATA M , Kiura K, Okimoto N, Segawa Y, et al
    A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
31. FINE RL , Shah SS, Moulton TA, Yu IR, et al
    Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy.
    Cancer Chemother Pharmacol. 2007;59:429-37.
    PubMed     Related articles    Abstract available
    
    
    February 2007
32. HIROSE T , Shirai T, Ishida H, Ando K, et al
    Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
33. CASAL J , Amenedo M, Mel JR, Anton LM, et al
    Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
    Cancer Chemother Pharmacol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    January 2007
34. MOREB JS , Mohuczy D, Ostmark B, Zucali JR, et al
    RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide.
    Cancer Chemother Pharmacol. 2007;59:127-36.
    PubMed     Related articles    Abstract available
    
    
    December 2006
35. KAWAMURA M , Eguchi K, Izumi Y, Yamato Y, et al
    Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    November 2006
36. WANG L , Wu X, Huang M, Cai J, et al
    The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
37. MORI K , Kamiyama Y, Kondo T, Kano Y, et al
    Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy.
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
38. JOHNSON BE , Jackman D, Janne PA
    Impact of EGFR mutations on treatment of non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
39. PAO W
    Defining clinically relevant molecular subsets of lung cancer.
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
40. YATABE Y
    Molecular classification of tumors with special reference to EGFR mutation in lung cancer.
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
41. TOYOOKA S , Soh J, Shigematsu H, Aoe M, et al
    The impact and role of EGFR gene mutation on non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
42. ICHINOSE Y
    A randomized phase III trial of adjuvant treatment for resected non-small cell lung cancer in Japan.
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    October 2006
43. COHEN RB , Langer CJ, Simon GR, Eisenberg PD, et al
    A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
44. BINDER D , Schweisfurth H, Grah C, Schaper C, et al
    Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    September 2006
45. TABATA M , Kozuki T, Ueoka H, Kiura K, et al
    A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
    Cancer Chemother Pharmacol. 2006;.
    PubMed     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Bernd Sebastian Kamps website.    Design: